DPTIP is a selective, potent (IC50 = 30 nM), and brain penetrant inhibitor of neutral sphingomyelinase 2 (nSMase2).1 In a mouse model of brain injury, it inhibited IL-1ß-induced astrocyte-derived extracellular vesicle release which reduced cytokine upregulation and attenuation of infiltration of immune cells to the brain leading to decreased inflammation. DPTIP displayed potent antiviral activity against Zika and West Nile viruses (EC50 Vero cells: 0.26 µM and 1.56 µM respectively).2 DPTIP acted synergistically with enzalutamide to significantly suppress cell proliferation, colony formation, and migration of metastatic castration resistant prostate cancer cells.3 It also reduced tumor size and weight in a prostate cancer mouse model.
* VAT and and shipping costs not included. Errors and price changes excepted
